FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4298145412> ?p ?o ?g. }

• W4298145412 abstract "Background: This study assessed the effects of esmolol injection in patients with in-hospital cardiac arrest (IHCA) with refractory ventricular fibrillation (VF)/pulseless ventricular tachycardia (pVT). Methods: From January 2018 to December 2021, 29 patients with IHCA with refractory shockable rhythm were retrospectively reviewed. Esmolol was administered after advanced cardiovascular life support (ACLS)-directed procedures, and outcomes were assessed. Results: Among the 29 cases, the rates of sustained return of spontaneous circulation (ROSC), 24-h ROSC, and 72-h ROSC were 79%, 62%, and 59%, respectively. Of those patients, 59% ultimately survived to discharge. Four patients with cardiac insufficiency died. The duration from CA to esmolol infusion was significantly shorter for patients in the survival group (SG) than for patients in the dead group (DG) (12 min, IQR: 8.5-19.5 vs. 23.5 min, IQR: 14.4-27 min; p = 0.013). Of those patients, 76% (22 of 29) started esmolol administration after the second dose of amiodarone. No significant difference was observed in the survival rate between this group and groups administered an esmolol bolus simultaneously or before the second dose of amiodarone (43% vs. 64%, p = 0.403). Of those patients, 31% (9 of 29) were administered an esmolol bolus for defibrillation attempts ≤ 5, while the remaining 69% of patients received an esmolol injection after the fifth defibrillation attempt. No significant differences were observed in the rates of ≥ 24-h ROSC (67% vs. 60%, p = 0.73), ≥ 72-h ROSC (67% vs. 55%, p = 0.56), and survival to hospital discharge (67% vs. 55%, p = 0.56) between the groups administered an esmolol bolus for defibrillation attempts ≤ 5 and defibrillation attempts > 5. Conclusion: IHCA patients with refractory shockable rhythms receiving esmolol bolus exhibited a high chance of sustained ROSC and survival to hospital discharge. Patients with end-stage heart failure tended to have attenuated benefits from beta-blockers. Further large-scale, prospective studies are necessary to determine the effects of esmolol in patients with IHCA with refractory shockable rhythms." @default.
• W4298145412 created "2022-10-01" @default.
• W4298145412 creator A5003732390 @default.
• W4298145412 creator A5017412474 @default.
• W4298145412 creator A5018478553 @default.
• W4298145412 creator A5019812152 @default.
• W4298145412 creator A5021379796 @default.
• W4298145412 creator A5028872220 @default.
• W4298145412 creator A5034423792 @default.
• W4298145412 creator A5045106317 @default.
• W4298145412 creator A5046662102 @default.
• W4298145412 creator A5057505964 @default.
• W4298145412 creator A5061136925 @default.
• W4298145412 creator A5066102428 @default.
• W4298145412 creator A5091537321 @default.
• W4298145412 date "2022-09-30" @default.
• W4298145412 modified "2023-09-30" @default.
• W4298145412 title "The first case series analysis on efficacy of esmolol injection for in-hospital cardiac arrest patients with refractory shockable rhythms in China" @default.
• W4298145412 cites W1963838778 @default.
• W4298145412 cites W1968568031 @default.
• W4298145412 cites W1980831063 @default.
• W4298145412 cites W1981859751 @default.
• W4298145412 cites W1990638882 @default.
• W4298145412 cites W2002169055 @default.
• W4298145412 cites W2008330779 @default.
• W4298145412 cites W2009042019 @default.
• W4298145412 cites W2010626010 @default.
• W4298145412 cites W2011541483 @default.
• W4298145412 cites W2020908699 @default.
• W4298145412 cites W2025123704 @default.
• W4298145412 cites W2029344075 @default.
• W4298145412 cites W2038593465 @default.
• W4298145412 cites W2040552151 @default.
• W4298145412 cites W2046261651 @default.
• W4298145412 cites W2048619616 @default.
• W4298145412 cites W2049816064 @default.
• W4298145412 cites W2050412135 @default.
• W4298145412 cites W2053240813 @default.
• W4298145412 cites W2075963626 @default.
• W4298145412 cites W2098091435 @default.
• W4298145412 cites W2108435498 @default.
• W4298145412 cites W2115253753 @default.
• W4298145412 cites W2146192724 @default.
• W4298145412 cites W2152966419 @default.
• W4298145412 cites W2155383869 @default.
• W4298145412 cites W2155987968 @default.
• W4298145412 cites W2165476711 @default.
• W4298145412 cites W2168109637 @default.
• W4298145412 cites W2169357282 @default.
• W4298145412 cites W2286368939 @default.
• W4298145412 cites W2318257564 @default.
• W4298145412 cites W2330803558 @default.
• W4298145412 cites W2414528801 @default.
• W4298145412 cites W2518612485 @default.
• W4298145412 cites W2807029594 @default.
• W4298145412 cites W2883159984 @default.
• W4298145412 cites W2883711719 @default.
• W4298145412 cites W2921398984 @default.
• W4298145412 cites W2983105482 @default.
• W4298145412 cites W2989972058 @default.
• W4298145412 cites W2991406948 @default.
• W4298145412 cites W3009017598 @default.
• W4298145412 cites W3097845877 @default.
• W4298145412 cites W3138435965 @default.
• W4298145412 cites W4200622461 @default.
• W4298145412 cites W4205255286 @default.
• W4298145412 cites W4246169830 @default.
• W4298145412 cites W3152166083 @default.
• W4298145412 doi "https://doi.org/10.3389/fphar.2022.930245" @default.
• W4298145412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36249764" @default.
• W4298145412 hasPublicationYear "2022" @default.
• W4298145412 type Work @default.
• W4298145412 citedByCount "1" @default.
• W4298145412 countsByYear W42981454122023 @default.
• W4298145412 crossrefType "journal-article" @default.
• W4298145412 hasAuthorship W4298145412A5003732390 @default.
• W4298145412 hasAuthorship W4298145412A5017412474 @default.
• W4298145412 hasAuthorship W4298145412A5018478553 @default.
• W4298145412 hasAuthorship W4298145412A5019812152 @default.
• W4298145412 hasAuthorship W4298145412A5021379796 @default.
• W4298145412 hasAuthorship W4298145412A5028872220 @default.
• W4298145412 hasAuthorship W4298145412A5034423792 @default.
• W4298145412 hasAuthorship W4298145412A5045106317 @default.
• W4298145412 hasAuthorship W4298145412A5046662102 @default.
• W4298145412 hasAuthorship W4298145412A5057505964 @default.
• W4298145412 hasAuthorship W4298145412A5061136925 @default.
• W4298145412 hasAuthorship W4298145412A5066102428 @default.
• W4298145412 hasAuthorship W4298145412A5091537321 @default.
• W4298145412 hasBestOaLocation W42981454121 @default.
• W4298145412 hasConcept C121332964 @default.
• W4298145412 hasConcept C126322002 @default.
• W4298145412 hasConcept C142424586 @default.
• W4298145412 hasConcept C164705383 @default.
• W4298145412 hasConcept C2777055891 @default.
• W4298145412 hasConcept C2777795826 @default.
• W4298145412 hasConcept C2777953023 @default.
• W4298145412 hasConcept C2778094803 @default.
• W4298145412 hasConcept C2778165595 @default.
• W4298145412 hasConcept C2778619729 @default.
• W4298145412 hasConcept C2779161974 @default.

• next